G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$7.08 USD
-0.01 (-0.14%)
Updated Aug 12, 2024 12:54 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 41 - 60 ( 357 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q22 Results; Cosela Sales Picking Up; Data From Two Studies Expected Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trilaciclib PRESERVE(1)s Myeloprotection Status But Throws a Curveball for ORR
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Mixed Results From Phase 3 PRESERVE 1 Trial of Cosela in mCRC; Trial Terminated But Other Trials Proceeding
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Pivotal Data in CRC Expected Next Month; Investors Should Focus More on Potential Larger Indications Than ES-SCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2023 TKI Outlook: Bullseye: What?s a Hit in Targeted Oncology in 2023?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
CRC Data In February Could Give Cosela a New Launch
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Initial Bladder Data In-Line with Expectations; CRC Data Later This Quarter
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D